147 related articles for article (PubMed ID: 1515882)
1. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting.
Lazarus HM; Goodnough LT; Goldwasser E; Long G; Arnold JL; Strohl KP
Bone Marrow Transplant; 1992 Jul; 10(1):71-5. PubMed ID: 1515882
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
[TBL] [Abstract][Full Text] [Related]
3. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
4. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Chao NJ; Schriber JR; Long GD; Negrin RS; Catolico M; Brown BW; Miller LL; Blume KG
Blood; 1994 May; 83(10):2823-8. PubMed ID: 7514046
[TBL] [Abstract][Full Text] [Related]
7. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.
Locatelli F; Zecca M; Pedrazzoli P; Prete L; Quaglini S; Comoli P; De Stefano P; Beguin Y; Robustelli della Cuna G; Severi F
Bone Marrow Transplant; 1994 Apr; 13(4):403-10. PubMed ID: 8019464
[TBL] [Abstract][Full Text] [Related]
8. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation.
Abedi MR; Bäckman L; Boström L; Lindbäck B; Ringdén O
Bone Marrow Transplant; 1990 Aug; 6(2):121-6. PubMed ID: 2207449
[TBL] [Abstract][Full Text] [Related]
9. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.
Klaesson S; Ringdén O; Ljungman P; Lönnqvist B; Wennberg L
Bone Marrow Transplant; 1994 Apr; 13(4):397-402. PubMed ID: 8019463
[TBL] [Abstract][Full Text] [Related]
10. Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity.
Davies SV; Fegan CD; Kendall R; Beguin Y; Cavill I
Clin Lab Haematol; 1995 Jun; 17(2):139-44. PubMed ID: 8536416
[TBL] [Abstract][Full Text] [Related]
11. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
12. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
[TBL] [Abstract][Full Text] [Related]
15. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy.
Schapira L; Antin JH; Ransil BJ; Antman KH; Eder JP; McGarigle CJ; Goldberg MA
Blood; 1990 Dec; 76(11):2354-9. PubMed ID: 2257306
[TBL] [Abstract][Full Text] [Related]
16. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
[TBL] [Abstract][Full Text] [Related]
17. Serum colony stimulating factors in patients undergoing bone marrow transplantation: enhancing effect of recombinant human GM-CSF.
Geissler D; Niederwieser D; Aulitzky WE; Tilg H; Grünewald K; Huber C; Konwalinka G
Behring Inst Mitt; 1988 Aug; (83):289-300. PubMed ID: 3071343
[TBL] [Abstract][Full Text] [Related]
18. Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation.
Bosi A; Vannucchi AM; Grossi A; Guidi S; Vannucchi L; Saccardi R; Bernabei PA; Longo G; Rafanelli D; Rossi-Ferrini P
Bone Marrow Transplant; 1991 Jun; 7(6):421-5. PubMed ID: 1873588
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
20. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
